Page 5,571«..1020..5,5705,5715,5725,573..5,5805,590..»

Professor: Genetic mutations can amplify drug addictions

Posted: Published on March 16th, 2013

Published: Thursday, March 14, 2013 at 5:13 p.m. Last Modified: Thursday, March 14, 2013 at 5:13 p.m. That some people are genetically prone to addictions is nothing new, but some scientists have expressed surprise at the degree of addictive tendencies. For example, if you have a high-risk genotype for marijuana addiction and also suffer from neuroticism or anxiety, you have an eight- to nine-fold risk of becoming addicted to marijuana. What's more, in-utero exposure to the drug might induce long-term addictive tendencies at least in rats. Professor Yasmin Hurd, a neuroscientist and professor of psychiatry at the Ichan School of Medicine in Mount Sinai, N.Y., cited these examples Thursday in a talk titled "The Vulnerable Brain: Understanding the Neurobiology of Addiction Risk." Her talk was one of two expert lectures delivered Thursday at the McKnight Brain Institute as part of brain awareness week, a global campaign to raise awareness of the brain. Early addiction research in neuroscience focused on dopamine dependence the "feel-good" chemical released abundantly in the brain when people use drugs. The flip side of this immediate surge is a long-term lessening of dopamine actually produced by the brain, which over time, decreases a person's ability to experience … Continue reading →

Comments Off on Professor: Genetic mutations can amplify drug addictions

Lorna Tolentino, magbabakasyon at magpapa- stem cell therapy pagkatapos ng Pahiram…

Posted: Published on March 16th, 2013

Pangunahing tampok dito sina Lorna Tolentino, Dingdong Dantes, Max Collins, Alessandra de Rossi, Neil Ryan Sese, at Christopher de Leon. Isa ito sa hindi ko malilimutan na teleserye, sabi ni Lorna nang makausap ng PEP.ph (Philippine Entertainment Portal) sa Party Pilipinas last Sunday, March 10. Napakaganda ng istorya. "Sa story, yung ending, hindi ko talaga iniisip na ganun ang mangyayari. Ang ganda ng pagkakasulat ng mga writer. At siyempre, maganda rin yung pagkakadirek ni Direk Maryo J. de los Reyes. At sa cast, wala talagang hindi nagbigay ng kanilang one hundred percent. WISH FOR NEXT PROJECT. Pagkatapos ng Pahiram Ng Sandali, ano ang sunod na klase ng project na gusto niyang gawin sa GMA-7 pa rin? Kung sana merong iba naman na ano siyempre kapag mabait na mabait ka, gusto mo naman mas salbahe ka sa susunod, di ba? Para naman medyo may variety, na medyo kakaiba dun sa natapos ko. Sana mabigyan ako ng medyo offbeat naman. Read more: Lorna Tolentino, magbabakasyon at magpapa- stem cell therapy pagkatapos ng Pahiram... … Continue reading →

Comments Off on Lorna Tolentino, magbabakasyon at magpapa- stem cell therapy pagkatapos ng Pahiram…

2013 Stem Cell Therapy #1 – Video

Posted: Published on March 15th, 2013

2013 Stem Cell Therapy #1 Introduction to 11 weeks of stem cell therapy in Delhi with Dr Geeta Shroff By: Louis Rowe … Continue reading →

Comments Off on 2013 Stem Cell Therapy #1 – Video

Stem Cell Treatments for Rheumatoid Arthritis and MS at Stem Cell Institute in Panama: Tracey R. – Video

Posted: Published on March 15th, 2013

Stem Cell Treatments for Rheumatoid Arthritis and MS at Stem Cell Institute in Panama: Tracey R. Stem Cell Treatments for Rheumatoid Arthritis and MS at Stem Cell Institute in Panama Tracey R. Uploaded by cellmedicine on Mar 12 2013. Tracey Renneberg discusses her improvements following stem cell therapy for rheumatoid arthritis Tracey is now in Panama multiple sclerosis treatmentMy rheumatoid arthritis is completely gone This leg used to drag and now I can pick it up and walk If patients have rheumatoid arthritis or MS this is where they should be Rheumatoid arthritis treatment ... By: cellmedicine … Continue reading →

Posted in Stem Cell Treatments | Comments Off on Stem Cell Treatments for Rheumatoid Arthritis and MS at Stem Cell Institute in Panama: Tracey R. – Video

Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update

Posted: Published on March 15th, 2013

ROCKVILLE, Md., March 15, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trial programs and reported its 2012 financial results for the year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) "2012 saw the company achieve success in all of its Phase I clinical trial objectives," said Karl Johe, Ph.D., Neuralstem's Chairman of the Board and Chief Scientific Officer. "We have been able to demonstrate the safety and tolerability of Neuralstem's novel core technologies, from intraspinal transplantation procedures, to the cells themselves in ALS patients, as well as our NSI-189 neurogenic small molecule drug in healthy volunteers. Additionally, we believe we have seen evidence of a treatment effect in some NSI-566 cell therapy patients over a sustained period of time, as measured by levels of functional recovery and a slowdown in the progression of ALS. In spinal cord injury, a leading peer-reviewed scientific journal, 'CELL,' published compelling evidence that NSI-566 cells can 'bridge the gap' in a severed spinal cord animal model and return functionality.We have recently been approved by the FDA to commence a trial treating chronic spinal cord injury patients. A highlight of 2012 was the completion of our ground-breaking ALS Phase I trial. … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update

Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan

Posted: Published on March 15th, 2013

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has gained global development and commercialization rights to Ligand Pharmaceuticals (NASDAQ: LGND) Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We are pleased to have forged this agreement Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization. We are pleased to add this late-stage program to our portfolio, which includes belinostat, for which we anticipate an NDA filing mid-year, and apaziquone, for which we expect to file an NDA in 2014, stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. Captisol-enabled melphalan is designed to meet the need for a formulation of melphalan that is free of propylene glycol, which … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan

Cytomedix to Present at the Canaccord Genuity Musculoskeletal Conference

Posted: Published on March 15th, 2013

GAITHERSBURG, MD--(Marketwire - Mar 15, 2013) - Cytomedix, Inc. ( OTCQX : CMXI ), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Edward Field, the Company's Chief Operating Officer, has been invited to make a presentation at the Canaccord Genuity Musculoskeletal Conference, which will be held on Tuesday, March 19, 2013. Presentation Details Time: Tuesday, March 19 at 8:30am CT / 9.30am EDT Room: Huron A Room, Track III Location: Westin Michigan Avenue, 909 North Michigan Avenue, Chicago A live webcast of the presentation may be accessed through the Company's website at http://www.cytomedix.com. A replay of the webcast will be available for one week following the conference. Cytomedix will also be hosting an exhibit at the American Academy of Orthopedic Surgeons (AAOS) annual meeting, which will take place, March 19th - 22nd at the McCormick Place convention center in Chicago. Please visit the Company at booth #4453. About the Canaccord Genuity Musculoskeletal ConferenceThe Canaccord Genuity Musculoskeletal Conference will explore the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies. This event is expected to have 60 companies present, both public and private. The conference directly precedes … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Cytomedix to Present at the Canaccord Genuity Musculoskeletal Conference

How to repair cartilage in osteoarthritis… the role of stem cell matrix – Video

Posted: Published on March 15th, 2013

How to repair cartilage in osteoarthritis... the role of stem cell matrix http://www.stemcellsarthritistreatment.com So I want to tell you something about adult stem cell therapy. Stem cells need something to cling to if they're going to become cartilage. That something is called a matrix or scaffold. So what are the ideal properties of a scaffold? They need to be biocompatible so inflammation doesn't damage the host. Second, they need to have a 3-dimentional shape to allow cell differentiation and multiplication. Third, they need to be porous to allow diffusion of nutrients and oxygen as well as passage of cells. Fourth, the scaffold should permit adhesion or sticking of the stem cells to it. Fifth, the scaffold should participate in the growth process by releasing growth factors. Sixth, the matrix should stick to the host tissue. Seventh, the scaffold must maintain its shape during the growth phase and also degrade during the remodeling phase. Eighth, the scaffold should be able to be implanted using minimally invasive procedures. Only then will a true alternative to knee replacement surgery be possible. http By: Nathan Wei … Continue reading →

Comments Off on How to repair cartilage in osteoarthritis… the role of stem cell matrix – Video

Six months after stem cell treatment for lax shoulder/chronic sprained ankle from Dr Harry Adelson – Video

Posted: Published on March 15th, 2013

Six months after stem cell treatment for lax shoulder/chronic sprained ankle from Dr Harry Adelson Nick discusses the outcome from his stem cell treatment for a lax shoulder joint and ankle pain from multiple sprains By: Harry Adelson … Continue reading →

Comments Off on Six months after stem cell treatment for lax shoulder/chronic sprained ankle from Dr Harry Adelson – Video

March 2013 Walking update ~ Stem Cell Treatment – Video

Posted: Published on March 15th, 2013

March 2013 Walking update ~ Stem Cell Treatment msrelief.com I am feeling very strong after the Stem cell treatment about three weeks ago. I am able to do exercises that I haven't been able to do for months. I will continue to exercise, eat, sleep, pray and we'll see what the future has in store! By: findjoymsrelief … Continue reading →

Comments Off on March 2013 Walking update ~ Stem Cell Treatment – Video

Page 5,571«..1020..5,5705,5715,5725,573..5,5805,590..»